title: What will be required to bring ⁶⁸Ga-labelled peptides into routine clinical use?
authors.forename: James R
authors.initials: JR
authors.lastname: Ballinger
authors.forename: Kishor K
authors.initials: KK
authors.lastname: Solanki
mesh_terms: D005710:Gallium Radioisotopes; D006801:Humans; D064847:Multimodal Imaging / Q000379:methods*; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging*; D015282:Octreotide / Q000031:analogs & derivatives* / Q000138:chemical synthesis; D049268:Positron-Emission Tomography; D017410:Practice Guidelines as Topic; D011876:Radionuclide Generators / Q000331:legislation & jurisprudence; D019275:Radiopharmaceuticals / Q000138:chemical synthesis; D013667:Technetium; D014057:Tomography, X-Ray Computed; D006113:United Kingdom
chemical_list: D005710:Gallium Radioisotopes; D019275:Radiopharmaceuticals; D013667:Technetium; D015282:Octreotide; C106246:Edotreotide